Akorn Recalls Erythromycin Pledgets Due to Microbial Contamination
Akorn, Inc. is recalling Erythromycin Pledgets USP, 2%, 60-count jars because the active pharmaceutical ingredient failed USP microbial tests.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a 'Severe' rating under the rubric, particularly given the risk of microbial contamination in a pharmaceutical product.
Plain-English summary
Akorn, Inc. is recalling Erythromycin Pledgets USP, 2%, 60-count jars, which are prescription-only products. The recall was initiated because the active pharmaceutical ingredient (API) failed USP microbial tests, indicating microbial contamination of the non-sterile product.
The affected product is manufactured by Ei LLC in Kannapolis, NC, and marketed by VersaPharm Incorporated in Marietta, GA. The specific NDC number is 61748-202-60. A total of 23,449 jars are involved in this recall, which has a nationwide distribution pattern.
The affected lots include Lot # 1446800 (Exp. 03/15), Lot # 1538100 (Exp. 05/15), Lot # 1538101 (Exp. 05/15), Lot # 1538200 (Exp. 06/15), and Lot # 1608200 (Exp. 08/15). Consumers and healthcare providers should check their inventory for these specific lot numbers and expiration dates. If the product matches the recalled description, it should be returned to the pharmacy or supplier for a refund or replacement, or disposed of according to local regulations.
The recalled product
- Product
- Erythromycin Pledgets USP, 2%, 60-count jar,Rx only, Manufactured by Ei LLC, Kannapolis, NC 28083, Marketed by VersaPharm Incorporated, Marietta, GA 30062, NDC 61748-202-60 .
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Antibiotic
- Hazard
- Affected units
- 23,449
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot # 1446800
- Exp. 03/15 Lot # 1538100
- Exp. 05/15 Lot # 1538101
- Exp. 05/15 Lot # 1538200
- Exp. 06/15 Lot # 1608200
- Exp. 08/15
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · microbial contamination
See all →- HighSV Labs Recalls Benzoyl Peroxide Wash Due to Microbial Contamination
FDA (Drugs) · 2026-10-07
- HighSV Labs Recalls Benzoyl Peroxide Wash Due to Microbial Contamination
FDA (Drugs) · 2026-10-07
- SevereMedline Ultrasound Breast Pack Recalled for Potential Sterility Breach
FDA (Devices) · 2026-09-09
- HighMedline Convenience Kits Recalled for Potential Sterility Breach
FDA (Devices) · 2026-09-09
- CriticalOptimal Balance Pharmacy Recalls Contaminated Glutathione Injection Vials
FDA (Drugs) · 2026-09-09
Similar recalls
- LowAkorn Recalls Desoximetasone Gel Due to Impurity Specification Failure
FDA (Drugs) · 2016-08-31
- ModerateAkorn Recalls Clindamycin Phosphate Topical Solution Due to Impurity Failures
FDA (Drugs) · 2018-12-05
- HighFDA Recalls Nationwide Supply of Erythromycin Ophthalmic Ointment for Manufacturing Deviations
FDA (Drugs) · 2023-01-25
- LowAkorn Recalls Nystatin Oral Suspension Due to Unknown Impurity
FDA (Drugs) · 2019-04-10
- ModerateDrug Recall: Erythromycin Ophthalmic Ointment Due to Manufacturing Deviations
FDA (Drugs) · 2023-01-25
- LowAkorn Recalls RIFAMPIN FOR INJECTION Due to Impurity Specifications
FDA (Drugs) · 2015-11-25